董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer A. Doudna | 女 | Independent Director | 62 | 18.82万美元 | 1.06 | 2026-08-31 |
| Wayne A.I. Frederick | 男 | Independent Director | 54 | 18.72万美元 | 1.67 | 2026-08-31 |
| Nadja West | 女 | Independent Director | 65 | 18.72万美元 | 2.10 | 2026-08-31 |
| Wayne A.I. Frederick | 男 | Independent Director | 55 | 未披露 | 未持股 | 2026-08-31 |
| Scott Gottlieb | 男 | Independent Director | 53 | 18.72万美元 | 1.67 | 2026-08-31 |
| Eric Lefkofsky | 男 | Chairman of the Board,Chief Executive Officer and Director | 56 | 4149.58万美元 | 未持股 | 2026-08-31 |
| Eric D. Belcher | 男 | Independent Director | 57 | 18.72万美元 | 2.14 | 2026-08-31 |
| Peter J. Barris | 男 | Independent Director | 74 | 19.97万美元 | 10.74 | 2026-08-31 |
| Theodore J. Leonsis | 男 | Independent Director | 70 | 18.72万美元 | 7.42 | 2026-08-31 |
| David R. Epstein | 男 | Independent Director | 64 | 18.72万美元 | 1.17 | 2026-08-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ryan Fukushima | 男 | Chief Executive Officer, Data | 41 | 1160.23万美元 | 63.05 | 2026-08-31 |
| Andrew Polovin | 男 | Executive Vice President, Chief Legal Officer and Secretary | 52 | 658.26万美元 | 3.82 | 2026-08-31 |
| James Rogers | 男 | Chief Financial Officer | 40 | 635.62万美元 | 0.24 | 2026-08-31 |
| Tom Schoenherr | 男 | Chief Executive Officer, Diagnostics | 52 | 未披露 | 未持股 | 2026-08-31 |
| Eric Lefkofsky | 男 | Chairman of the Board,Chief Executive Officer and Director | 56 | 4149.58万美元 | 未持股 | 2026-08-31 |
董事简历
中英对照 | 中文 | 英文- Jennifer A. Doudna
-
Jennifer A. Doudna于2002年加入加州大学伯克利分校，担任生物化学和分子生物学教授。她是加州大学伯克利分校和旧金山分校联合中心创新基因研究所的负责人，拥有李嘉诚校长生物医学与健康教授职位，是加州大学伯克利分校校长生物咨询委员会主席。Doudna博士是加州大学伯克利分校Doudna实验室的主要研究人员，曾在驯鹿生物科学公司（Caribou Biosciences，Inc.）和Intellia Therapeutics，Inc.的科学咨询委员会任职，这两家都是领先的CRISPR基因组工程公司。自1997年以来，她一直是霍华德休斯医学研究所的研究员。Doudna博士是众多生物化学和遗传学科学奖的获得者，包括2020年的诺贝尔化学奖。杜德纳博士是波莫纳学院的受托人。
Jennifer A. Doudna has served as a member of the Tempus Board since April 2021 and is a member of the Nominating and Corporate Governance Committee. Dr. Doudna has also served on the board of directors of Johnson & Johnson since April 2018. Since July 2002, Dr. Doudna has served as a Professor of Biochemistry & Molecular Biology at the University of California, Berkeley, where she directs the Innovative Genomics Institute, a joint UC Berkeley UC San Francisco center, holds the Li Ka Shing Chancellor's Professorship in Biomedical and Health, and is the Chair of the Chancellor's Advisory Committee on Biology. Since 2002, Dr. Doudna has served as Principal Investigator at the Doudna Lab at UC Berkeley. Dr. Doudna has founded and served on the Scientific Advisory Boards of Caribou Biosciences, Inc. and Intellia Therapeutics, Inc., both leading CRISPR genome engineering companies, since 2010. She has also been an Investigator with the Howard Hughes Medical Institute since 1997. Dr. Doudna is the recipient of numerous scientific awards in biochemistry and genetics, including the Nobel Prize in Chemistry in 2020. Dr. Doudna holds a bachelor's degree from Pomona College and a Ph.D. from Harvard Medical School. - Jennifer A. Doudna于2002年加入加州大学伯克利分校，担任生物化学和分子生物学教授。她是加州大学伯克利分校和旧金山分校联合中心创新基因研究所的负责人，拥有李嘉诚校长生物医学与健康教授职位，是加州大学伯克利分校校长生物咨询委员会主席。Doudna博士是加州大学伯克利分校Doudna实验室的主要研究人员，曾在驯鹿生物科学公司（Caribou Biosciences，Inc.）和Intellia Therapeutics，Inc.的科学咨询委员会任职，这两家都是领先的CRISPR基因组工程公司。自1997年以来，她一直是霍华德休斯医学研究所的研究员。Doudna博士是众多生物化学和遗传学科学奖的获得者，包括2020年的诺贝尔化学奖。杜德纳博士是波莫纳学院的受托人。
- Jennifer A. Doudna has served as a member of the Tempus Board since April 2021 and is a member of the Nominating and Corporate Governance Committee. Dr. Doudna has also served on the board of directors of Johnson & Johnson since April 2018. Since July 2002, Dr. Doudna has served as a Professor of Biochemistry & Molecular Biology at the University of California, Berkeley, where she directs the Innovative Genomics Institute, a joint UC Berkeley UC San Francisco center, holds the Li Ka Shing Chancellor's Professorship in Biomedical and Health, and is the Chair of the Chancellor's Advisory Committee on Biology. Since 2002, Dr. Doudna has served as Principal Investigator at the Doudna Lab at UC Berkeley. Dr. Doudna has founded and served on the Scientific Advisory Boards of Caribou Biosciences, Inc. and Intellia Therapeutics, Inc., both leading CRISPR genome engineering companies, since 2010. She has also been an Investigator with the Howard Hughes Medical Institute since 1997. Dr. Doudna is the recipient of numerous scientific awards in biochemistry and genetics, including the Nobel Prize in Chemistry in 2020. Dr. Doudna holds a bachelor's degree from Pomona College and a Ph.D. from Harvard Medical School.
- Wayne A.I. Frederick
-
Wayne A.I. Frederick，自2020年10月起担任董事会成员。自2024年11月2日起，他担任美国癌症协会及其倡导附属机构美国癌症协会癌症行动网络（ACS CAN）的临时首席执行官。他是Howard University College of Medicine杰出的Charles R. Drew外科教授，也是Howard University的名誉校长，此前曾担任Howard University的校长（2014年7月至2023年9月）。在2014年被任命为霍华德大学校长之前，他曾担任霍华德大学的教务长和首席学术官。Frederick博士是一名执业癌症外科医生，杰出的研究人员和学者，以及许多同行评审文章，书籍章节，摘要和社论的作者。作为医疗保健差异和医学教育领域公认的专家，他的医学研究重点是减少癌症治疗结果中的种族，民族和性别差异，特别强调胃肠道癌症。在他的职业生涯中，Frederick博士获得了许多认可，包括德克萨斯大学MD安德森癌症中心的杰出校友奖。2021年，他被纽约卡内基基金会（Carnegie Corporation of New York）表彰为加强美国做出贡献的34名入籍美国公民之一。他目前担任Humana， Inc., Tempus AI, Inc.和Workday， Inc.的董事会成员，并在担任临时首席执行官之前担任美国癌症协会董事会成员。他是几个专业协会的活跃成员，包括美国外科协会和美国外科医生学院。最近，他被任命为Mutual of America的高级独立董事，并担任波士顿咨询集团（Boston Consulting Group）的顾问。他获得了霍华德大学的理学学士、医学博士和工商管理硕士学位。
Wayne A.I. Frederick has served as a member of the Tempus Board since October 2020 and is a member of the Audit Committee. From November 2024 to August 2025, Dr. Frederick served as interim Chief Executive Officer of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network. Dr. Frederick has also served on the boards of directors of several other public companies, including serving as a member of the board of directors of Workday, Inc. since July 2022, Insulet Corp since October 2020 and Humana Inc. since February 2020. From July 2020 to October 2022, Dr. Frederick served as a member of the board of directors of Forma Therapeutics Holdings, Inc. He also serves on the boards of directors of privately held companies and charitable organizations. Dr. Frederick is currently the President Emeritus of Howard University, after serving as President since July 2014, and also serves as the Charles R. Drew Endowed Chair of Surgery at Howard University's College of Medicine. Dr. Frederick holds a B.S./M.D. dual degree, and an M.B.A. from Howard University. - Wayne A.I. Frederick，自2020年10月起担任董事会成员。自2024年11月2日起，他担任美国癌症协会及其倡导附属机构美国癌症协会癌症行动网络（ACS CAN）的临时首席执行官。他是Howard University College of Medicine杰出的Charles R. Drew外科教授，也是Howard University的名誉校长，此前曾担任Howard University的校长（2014年7月至2023年9月）。在2014年被任命为霍华德大学校长之前，他曾担任霍华德大学的教务长和首席学术官。Frederick博士是一名执业癌症外科医生，杰出的研究人员和学者，以及许多同行评审文章，书籍章节，摘要和社论的作者。作为医疗保健差异和医学教育领域公认的专家，他的医学研究重点是减少癌症治疗结果中的种族，民族和性别差异，特别强调胃肠道癌症。在他的职业生涯中，Frederick博士获得了许多认可，包括德克萨斯大学MD安德森癌症中心的杰出校友奖。2021年，他被纽约卡内基基金会（Carnegie Corporation of New York）表彰为加强美国做出贡献的34名入籍美国公民之一。他目前担任Humana， Inc., Tempus AI, Inc.和Workday， Inc.的董事会成员，并在担任临时首席执行官之前担任美国癌症协会董事会成员。他是几个专业协会的活跃成员，包括美国外科协会和美国外科医生学院。最近，他被任命为Mutual of America的高级独立董事，并担任波士顿咨询集团（Boston Consulting Group）的顾问。他获得了霍华德大学的理学学士、医学博士和工商管理硕士学位。
- Wayne A.I. Frederick has served as a member of the Tempus Board since October 2020 and is a member of the Audit Committee. From November 2024 to August 2025, Dr. Frederick served as interim Chief Executive Officer of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network. Dr. Frederick has also served on the boards of directors of several other public companies, including serving as a member of the board of directors of Workday, Inc. since July 2022, Insulet Corp since October 2020 and Humana Inc. since February 2020. From July 2020 to October 2022, Dr. Frederick served as a member of the board of directors of Forma Therapeutics Holdings, Inc. He also serves on the boards of directors of privately held companies and charitable organizations. Dr. Frederick is currently the President Emeritus of Howard University, after serving as President since July 2014, and also serves as the Charles R. Drew Endowed Chair of Surgery at Howard University's College of Medicine. Dr. Frederick holds a B.S./M.D. dual degree, and an M.B.A. from Howard University.
- Nadja West
-
Nadja West自2021年4月起担任Tempus董事会成员，并担任薪酬委员会成员。维斯特博士还曾在其他几家上市公司的董事会任职，包括自2020年12月起担任强生董事会成员、自2019年10月起担任泰尼特保健 Corp、自2019年9月起担任纽柯钢铁公司。2015年12月至2019年10月，韦斯特博士担任美国陆军第44任外科医生、美国陆军医疗司令部司令。韦斯特博士目前担任国家康乐基金会和圣玛丽山大学的受托人，以及伍德拉夫基金会的董事会成员。她还被任命为NCAA理事会的独立成员。韦斯特博士拥有美国西点军校的学士学位、乔治华盛顿大学医学院的医学博士学位和国立战争学院的硕士学位。
Nadja West has served as a member of the Tempus Board since April 2021 and is a member of the Compensation Committee. Dr. West has also served on the boards of directors of several other public companies, including serving as a member of the board of directors of Johnson & Johnson since December 2020, Tenet Healthcare Corp since October 2019, and Nucor Corporation since September 2019. From December 2015 to October 2019, Dr. West served as the 44th Surgeon General of the U.S. Army, and the Commanding General of the U.S. Army Medical Command. Dr. West currently serves as Trustee of both the National Recreation Foundation and Mount St. Mary's University, and board member of The Woodruff Foundation. She was also appointed an independent member of the NCAA Board of Governors. Dr. West holds a B.S. from the United States Military Academy at West Point, an M.D. from The George Washington University School of Medicine, and an M.S. from National War College. - Nadja West自2021年4月起担任Tempus董事会成员，并担任薪酬委员会成员。维斯特博士还曾在其他几家上市公司的董事会任职，包括自2020年12月起担任强生董事会成员、自2019年10月起担任泰尼特保健 Corp、自2019年9月起担任纽柯钢铁公司。2015年12月至2019年10月，韦斯特博士担任美国陆军第44任外科医生、美国陆军医疗司令部司令。韦斯特博士目前担任国家康乐基金会和圣玛丽山大学的受托人，以及伍德拉夫基金会的董事会成员。她还被任命为NCAA理事会的独立成员。韦斯特博士拥有美国西点军校的学士学位、乔治华盛顿大学医学院的医学博士学位和国立战争学院的硕士学位。
- Nadja West has served as a member of the Tempus Board since April 2021 and is a member of the Compensation Committee. Dr. West has also served on the boards of directors of several other public companies, including serving as a member of the board of directors of Johnson & Johnson since December 2020, Tenet Healthcare Corp since October 2019, and Nucor Corporation since September 2019. From December 2015 to October 2019, Dr. West served as the 44th Surgeon General of the U.S. Army, and the Commanding General of the U.S. Army Medical Command. Dr. West currently serves as Trustee of both the National Recreation Foundation and Mount St. Mary's University, and board member of The Woodruff Foundation. She was also appointed an independent member of the NCAA Board of Governors. Dr. West holds a B.S. from the United States Military Academy at West Point, an M.D. from The George Washington University School of Medicine, and an M.S. from National War College.
- Wayne A.I. Frederick
-
Wayne A.I. Frederick自2020年10月起担任Tempus董事会成员，并担任审计委员会成员。2024年11月至2025年8月，弗雷德里克博士担任美国癌症协会及其倡导附属机构美国癌症协会癌症行动网络的临时首席执行官。Frederick博士还曾在其他几家上市公司的董事会任职，包括自2022年7月起担任Workday，Inc.的董事会成员，自2020年10月起担任银休特 Corp.的董事会成员，自2020年2月起担任哈门那 Inc.的董事会成员。从2020年7月到2022年10月，Frederick博士担任Forma Therapeutics Holdings, Inc.的董事会成员。他还担任私人控股公司和慈善组织的董事会成员。弗雷德里克博士目前是霍华德大学的名誉校长，自2014年7月起担任校长，同时还担任霍华德大学医学院的Charles R. Drew捐赠的外科主席。Frederick博士拥有B.S./M.D.双学位，以及霍华德大学的MBA学位。
Wayne A.I. Frederick has served as a member of the Tempus Board since October 2020 and is a member of the Audit Committee. From November 2024 to August 2025, Dr. Frederick served as interim Chief Executive Officer of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network. Dr. Frederick has also served on the boards of directors of several other public companies, including serving as a member of the board of directors of Workday, Inc. since July 2022, Insulet Corp since October 2020 and Humana Inc. since February 2020. From July 2020 to October 2022, Dr. Frederick served as a member of the board of directors of Forma Therapeutics Holdings, Inc. He also serves on the boards of directors of privately held companies and charitable organizations. Dr. Frederick is currently the President Emeritus of Howard University, after serving as President since July 2014, and also serves as the Charles R. Drew Endowed Chair of Surgery at Howard University's College of Medicine. Dr. Frederick holds a B.S./M.D. dual degree, and an M.B.A. from Howard University. - Wayne A.I. Frederick自2020年10月起担任Tempus董事会成员，并担任审计委员会成员。2024年11月至2025年8月，弗雷德里克博士担任美国癌症协会及其倡导附属机构美国癌症协会癌症行动网络的临时首席执行官。Frederick博士还曾在其他几家上市公司的董事会任职，包括自2022年7月起担任Workday，Inc.的董事会成员，自2020年10月起担任银休特 Corp.的董事会成员，自2020年2月起担任哈门那 Inc.的董事会成员。从2020年7月到2022年10月，Frederick博士担任Forma Therapeutics Holdings, Inc.的董事会成员。他还担任私人控股公司和慈善组织的董事会成员。弗雷德里克博士目前是霍华德大学的名誉校长，自2014年7月起担任校长，同时还担任霍华德大学医学院的Charles R. Drew捐赠的外科主席。Frederick博士拥有B.S./M.D.双学位，以及霍华德大学的MBA学位。
- Wayne A.I. Frederick has served as a member of the Tempus Board since October 2020 and is a member of the Audit Committee. From November 2024 to August 2025, Dr. Frederick served as interim Chief Executive Officer of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network. Dr. Frederick has also served on the boards of directors of several other public companies, including serving as a member of the board of directors of Workday, Inc. since July 2022, Insulet Corp since October 2020 and Humana Inc. since February 2020. From July 2020 to October 2022, Dr. Frederick served as a member of the board of directors of Forma Therapeutics Holdings, Inc. He also serves on the boards of directors of privately held companies and charitable organizations. Dr. Frederick is currently the President Emeritus of Howard University, after serving as President since July 2014, and also serves as the Charles R. Drew Endowed Chair of Surgery at Howard University's College of Medicine. Dr. Frederick holds a B.S./M.D. dual degree, and an M.B.A. from Howard University.
- Scott Gottlieb
-
Scott Gottlieb，他自2009年1月起担任New Enterprise Associates，Inc.董事，从2019年起为美国企业研究所的常驻研究员。也是在纽约大学医学院的医学临床助理教授。从2005年到2007年，曾在美国食品和药物管理局“FDA”担任副处长，负责医学和科学事务。在此之前，从2003年到2004年担任FDA局长的医疗技术高级顾问和医疗FDA政策发展的董事。于2004年春离开了美国FDA，去完成新的医疗保险药物报销的工作，作为医疗保险和医疗补助服务中心的高级顾问，支持运用相关新的医疗技术，提高质量和覆盖范围和支付决策机构的政策工作。目前担任Molecular Insight Pharmaceuticals的董事。国家医学院院士，财经新闻网CNBC撰稿人，是Sinai School of Medicine和Connecticut Wesleyan University的毕业生。
Scott Gottlieb has served as a member of the Tempus Board since October 2019 and is a member of the Nominating and Corporate Governance Committee. Dr. Gottlieb has also served on the boards of directors of UnitedHealth Group since November 2025, Illumina, Inc. since February 2020 and Pfizer Inc. since June 2019. Dr. Gottlieb has served as a Partner on NEA's healthcare investment team since April 2019, and a Resident Fellow at American Enterprise Institute since April 2021. Prior to that, he served as the 23rd Commissioner of the U.S. Food and Drug Administration from May 2017 to April 2019. Prior to serving as Commissioner, Dr. Gottlieb held several roles in the public and private sectors, including serving as a Venture Partner at NEA from January 2007 to May 2017, and a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004. He is presently a contributor to CNBC and the CBS News program Face the Nation. He also currently serves on the executive committee of the Mount Sinai Health System's board of directors and co chairs the board's education committee. In addition, Dr. Gottlieb serves on the board of directors of Wesleyan University. Dr. Gottlieb holds a B.A. from Wesleyan University and an M.D. from Mount Sinai School of Medicine. - Scott Gottlieb，他自2009年1月起担任New Enterprise Associates，Inc.董事，从2019年起为美国企业研究所的常驻研究员。也是在纽约大学医学院的医学临床助理教授。从2005年到2007年，曾在美国食品和药物管理局“FDA”担任副处长，负责医学和科学事务。在此之前，从2003年到2004年担任FDA局长的医疗技术高级顾问和医疗FDA政策发展的董事。于2004年春离开了美国FDA，去完成新的医疗保险药物报销的工作，作为医疗保险和医疗补助服务中心的高级顾问，支持运用相关新的医疗技术，提高质量和覆盖范围和支付决策机构的政策工作。目前担任Molecular Insight Pharmaceuticals的董事。国家医学院院士，财经新闻网CNBC撰稿人，是Sinai School of Medicine和Connecticut Wesleyan University的毕业生。
- Scott Gottlieb has served as a member of the Tempus Board since October 2019 and is a member of the Nominating and Corporate Governance Committee. Dr. Gottlieb has also served on the boards of directors of UnitedHealth Group since November 2025, Illumina, Inc. since February 2020 and Pfizer Inc. since June 2019. Dr. Gottlieb has served as a Partner on NEA's healthcare investment team since April 2019, and a Resident Fellow at American Enterprise Institute since April 2021. Prior to that, he served as the 23rd Commissioner of the U.S. Food and Drug Administration from May 2017 to April 2019. Prior to serving as Commissioner, Dr. Gottlieb held several roles in the public and private sectors, including serving as a Venture Partner at NEA from January 2007 to May 2017, and a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004. He is presently a contributor to CNBC and the CBS News program Face the Nation. He also currently serves on the executive committee of the Mount Sinai Health System's board of directors and co chairs the board's education committee. In addition, Dr. Gottlieb serves on the board of directors of Wesleyan University. Dr. Gottlieb holds a B.A. from Wesleyan University and an M.D. from Mount Sinai School of Medicine.
- Eric Lefkofsky
-
Eric Lefkofsky，是该公司的联合创始人，自2013年8月5日创立以来担任公司执行董事长； 2013年2月28日以来在公司行政长官办事处任职，一直到2013年8月5日赴任首席执行官。Lefkofsky先生是Echo环球物流公司（NASDAQ代码： ECHO）的联合创始人， 2005年2月-2012年12月期间在该公司董事会任职。他也是InnerWorkings公司 （NASDAQ代码： INWK）的联合创始人，在2008年8月-2012年10月在该公司董事会任职。2008年，Lefkofsky联合创立了一家专门从事信息技术公司的私人投资公司- Lightbank有限责任公司，并从那时起担任经理。在2006年4月，Lefkofsky联合创立了一家促进广告媒体采购与管理自动化的电子交易与数据库的公司-MediaBank有限责任公司（现为Media Ocean），并从那时起担任董事或经理。Lefkofsky还分别在Children's Memorial 医院、Steppenwolf剧院、芝加哥美术馆（Art Institute of Chicago）、科学和工业博物馆（the Museum of Science and Industry）的董事会任职。Lefkofsky是芝加哥大学Booth商学院（the University of Chicago Booth School of Business）副教授；他拥有密歇根大学（he University of Chicago）的学士学位以及密歇根大学法学院（the University of Michigan Law School）的法学博士学位。
Eric Lefkofsky is Tempus' Founder, has served as its Chief Executive Officer and a member of the Tempus Board since its inception and is a member of the Executive Committee. Before founding Tempus, Mr. Lefkofsky co founded Groupon, Inc. in 2008, where he held various roles, including member of the board of directors (through November 2023), Chairman of the board of directors (November 2015 to June 2020), Executive Chairman (through August 2013) and Chief Executive Officer (August 2013 to November 2015). Mr. Lefkofsky also co founded Lightbank LLC in 2008, a private venture capital firm specializing in investments in technology companies, and has served as its managing member since inception and General Partner since January 2019. Mr. Lefkofsky also co founded InnerWorkings, Inc., Mediaocean, LLC, Echo Global Logistics, Inc., and Pathos AI, Inc., and served on each company's board of directors or board of managers. In addition, Mr. Lefkofsky has served on the board of directors of Northwestern Memorial Healthcare since February 2024. Mr. Lefkofsky holds a bachelor's degree from the University of Michigan and a J.D. from the University of Michigan Law School. - Eric Lefkofsky，是该公司的联合创始人，自2013年8月5日创立以来担任公司执行董事长； 2013年2月28日以来在公司行政长官办事处任职，一直到2013年8月5日赴任首席执行官。Lefkofsky先生是Echo环球物流公司（NASDAQ代码： ECHO）的联合创始人， 2005年2月-2012年12月期间在该公司董事会任职。他也是InnerWorkings公司 （NASDAQ代码： INWK）的联合创始人，在2008年8月-2012年10月在该公司董事会任职。2008年，Lefkofsky联合创立了一家专门从事信息技术公司的私人投资公司- Lightbank有限责任公司，并从那时起担任经理。在2006年4月，Lefkofsky联合创立了一家促进广告媒体采购与管理自动化的电子交易与数据库的公司-MediaBank有限责任公司（现为Media Ocean），并从那时起担任董事或经理。Lefkofsky还分别在Children's Memorial 医院、Steppenwolf剧院、芝加哥美术馆（Art Institute of Chicago）、科学和工业博物馆（the Museum of Science and Industry）的董事会任职。Lefkofsky是芝加哥大学Booth商学院（the University of Chicago Booth School of Business）副教授；他拥有密歇根大学（he University of Chicago）的学士学位以及密歇根大学法学院（the University of Michigan Law School）的法学博士学位。
- Eric Lefkofsky is Tempus' Founder, has served as its Chief Executive Officer and a member of the Tempus Board since its inception and is a member of the Executive Committee. Before founding Tempus, Mr. Lefkofsky co founded Groupon, Inc. in 2008, where he held various roles, including member of the board of directors (through November 2023), Chairman of the board of directors (November 2015 to June 2020), Executive Chairman (through August 2013) and Chief Executive Officer (August 2013 to November 2015). Mr. Lefkofsky also co founded Lightbank LLC in 2008, a private venture capital firm specializing in investments in technology companies, and has served as its managing member since inception and General Partner since January 2019. Mr. Lefkofsky also co founded InnerWorkings, Inc., Mediaocean, LLC, Echo Global Logistics, Inc., and Pathos AI, Inc., and served on each company's board of directors or board of managers. In addition, Mr. Lefkofsky has served on the board of directors of Northwestern Memorial Healthcare since February 2024. Mr. Lefkofsky holds a bachelor's degree from the University of Michigan and a J.D. from the University of Michigan Law School.
- Eric D. Belcher
-
Eric D. Belcher ，自2009年1月以来一直在本董事会任职，以及是本公司的首席执行官。在任首席执行官之前，他自2008年以来一直任本公司的总裁；他在2006年12月-2008年12月期间任本公司的首席运营官。在2005年5月-2006年12月期间，他曾担任本公司的业务副执行总裁。他曾在2003年3月-2005年6月期间在一家印刷设备的生产商和分销商-MAN Roland担任首席运营官，以及在2001年4月-2003年3月期间任财务总监。在1995-2000年期间，他曾在一家国际管理咨询公司- Marakon Associates管理项目团队。他拥有Bucknell大学的学士学位，以及在Chicago大学 Booth商学院获得的工商管理学硕士学位。他目前在Chicago Booth的波斯基创业中心的顾问委员会任职。
Eric D. Belcher has served as a member of the Tempus Board since January 2019 and is a member of the Audit Committee. Mr. Belcher has served as the Chief Executive Officer of Market Track, LLC (d/b/a Numerator), a data and technology company in the market research industry, since June 2019. Mr. Belcher has also held various positions at InnerWorkings, Inc. since May 2005, including most recently serving as its Chief Executive Officer and President from January 2009 to April 2018. Mr. Belcher served as a member of the board of directors of InnerWorkings, Inc. from January 2009 to December 2018, including as the Chairman of its board of directors from April 2018 to September 2018. Mr. Belcher holds a bachelor's degree from Bucknell University and an M.B.A. from the University of Chicago Booth School of Business. - Eric D. Belcher ，自2009年1月以来一直在本董事会任职，以及是本公司的首席执行官。在任首席执行官之前，他自2008年以来一直任本公司的总裁；他在2006年12月-2008年12月期间任本公司的首席运营官。在2005年5月-2006年12月期间，他曾担任本公司的业务副执行总裁。他曾在2003年3月-2005年6月期间在一家印刷设备的生产商和分销商-MAN Roland担任首席运营官，以及在2001年4月-2003年3月期间任财务总监。在1995-2000年期间，他曾在一家国际管理咨询公司- Marakon Associates管理项目团队。他拥有Bucknell大学的学士学位，以及在Chicago大学 Booth商学院获得的工商管理学硕士学位。他目前在Chicago Booth的波斯基创业中心的顾问委员会任职。
- Eric D. Belcher has served as a member of the Tempus Board since January 2019 and is a member of the Audit Committee. Mr. Belcher has served as the Chief Executive Officer of Market Track, LLC (d/b/a Numerator), a data and technology company in the market research industry, since June 2019. Mr. Belcher has also held various positions at InnerWorkings, Inc. since May 2005, including most recently serving as its Chief Executive Officer and President from January 2009 to April 2018. Mr. Belcher served as a member of the board of directors of InnerWorkings, Inc. from January 2009 to December 2018, including as the Chairman of its board of directors from April 2018 to September 2018. Mr. Belcher holds a bachelor's degree from Bucknell University and an M.B.A. from the University of Chicago Booth School of Business.
- Peter J. Barris
-
Peter J. Barris。自2003年担任董事。Barris。先生是New Enterprise Associates, Inc的执行普通合伙人，他在该公司中研究信息技术投资。Barris。先生自1992年起在New Enterprise Associates, Inc工作，是公司或公司其他实体公司的的普通合伙人。1988年至1990年，Barris。先生担任LEGENT Corporation的总裁兼首席运营官；1985年至1988年，他担任UCCEL Corporation的各项manment职位；1977年至1985年，他在General Electric Company担任各项管理职务，其中包括GE Information Services的副总裁，总经理等。Barris。先生同时是以下公司的董事会的董事：InnerWorkings, Inc.（纳斯达克代码： INWK），他是该公司审计，报偿，任命，公司管理委员会的成员；Vonage Holdings Corp（纳斯达克代码：VG），他是该公司报酬，任命，公司管理委员会的成员；Echo Global Logistics, Inc.（纳斯达克代码：ECHO），他是该公司任命，公司管理委员会的成员以及报偿委员会的董事长；Goji Food Solutions, Inc； Jobfox, Inc.；MBXG Holdings, Inc； SnagFilms, Inc；Hillcrest Laboratories, Inc.Barris。先生此前是Broadview Network Holdings, Inc以及Cyren Call Communications Corporation董事会的成员。他是In-Q-Tel and Northwestern University托管委员会的成员。
Peter J. Barris has served as a member of the Tempus Board since September 2017 and is a member of the Audit Committee, the Compensation Committee and the Executive Committee. Mr. Barris has served on the board of directors of Sprout Social, Inc. since February 2011. Previously, Mr. Barris served on the board of directors of Berkshire Grey, Inc. from April 2016 to July 2023, ZeroFox Holdings, Inc. from April 2014 to June 2023, NextNav Inc. from July 2014 to August 2022 and Groupon from January 2008 to August 2022. Mr. Barris joined New Enterprise Associates, Inc., or NEA, a global venture capital fund investing in technology and healthcare, where he specialized in information technology investing, in 1992 and retired at the end of 2019. Prior to his retirement, Mr. Barris held several roles at NEA, including Managing General Partner from 1999 to 2017. After retiring in 2019, Mr. Barris now serves as Chairman Emeritus of NEA. Mr. Barris also serves as Chairman Emeritus of Northwestern University. Mr. Barris holds a B.S. from Northwestern University and an M.B.A. from the Tuck School of Business at Dartmouth University. - Peter J. Barris。自2003年担任董事。Barris。先生是New Enterprise Associates, Inc的执行普通合伙人，他在该公司中研究信息技术投资。Barris。先生自1992年起在New Enterprise Associates, Inc工作，是公司或公司其他实体公司的的普通合伙人。1988年至1990年，Barris。先生担任LEGENT Corporation的总裁兼首席运营官；1985年至1988年，他担任UCCEL Corporation的各项manment职位；1977年至1985年，他在General Electric Company担任各项管理职务，其中包括GE Information Services的副总裁，总经理等。Barris。先生同时是以下公司的董事会的董事：InnerWorkings, Inc.（纳斯达克代码： INWK），他是该公司审计，报偿，任命，公司管理委员会的成员；Vonage Holdings Corp（纳斯达克代码：VG），他是该公司报酬，任命，公司管理委员会的成员；Echo Global Logistics, Inc.（纳斯达克代码：ECHO），他是该公司任命，公司管理委员会的成员以及报偿委员会的董事长；Goji Food Solutions, Inc； Jobfox, Inc.；MBXG Holdings, Inc； SnagFilms, Inc；Hillcrest Laboratories, Inc.Barris。先生此前是Broadview Network Holdings, Inc以及Cyren Call Communications Corporation董事会的成员。他是In-Q-Tel and Northwestern University托管委员会的成员。
- Peter J. Barris has served as a member of the Tempus Board since September 2017 and is a member of the Audit Committee, the Compensation Committee and the Executive Committee. Mr. Barris has served on the board of directors of Sprout Social, Inc. since February 2011. Previously, Mr. Barris served on the board of directors of Berkshire Grey, Inc. from April 2016 to July 2023, ZeroFox Holdings, Inc. from April 2014 to June 2023, NextNav Inc. from July 2014 to August 2022 and Groupon from January 2008 to August 2022. Mr. Barris joined New Enterprise Associates, Inc., or NEA, a global venture capital fund investing in technology and healthcare, where he specialized in information technology investing, in 1992 and retired at the end of 2019. Prior to his retirement, Mr. Barris held several roles at NEA, including Managing General Partner from 1999 to 2017. After retiring in 2019, Mr. Barris now serves as Chairman Emeritus of NEA. Mr. Barris also serves as Chairman Emeritus of Northwestern University. Mr. Barris holds a B.S. from Northwestern University and an M.B.A. from the Tuck School of Business at Dartmouth University.
- Theodore J. Leonsis
-
Theodore J. Leonsis，1999年以来他一直担任不朽体育及娱乐有限责任公司的董事长兼首席执行官，这是一家体育和娱乐公司在华盛顿特区和Verizon中心拥有NBA华盛顿奇才队，NHL华盛顿首都，WNBA华盛顿神秘主义者。他自2006年12月还担任美国在线公司名誉副主席，一家全球领先的广告网络公司。从1994年9月到2006年12月，他担任美国在线众多高管职位，比如说副主席和美国在线观众业务。他是Groupon公司的董事会主席。他也是一个导演，一个作家，几个私人网络和技术公司和教育机构的主人。他还是Revolution Money，Inc.的董事长，该公司是美国运通2010年1月取得的。2011年11月，他合伙成立了革命增长有限公司，加速投资科技企业。
Theodore J. Leonsis has served as a member of the Tempus Board since January 2019 and is a member of the Nominating and Corporate Governance Committee and the Executive Committee. In November 2011, Mr. Leonsis co founded Revolution Growth, a private investment firm, and has served as a General Partner thereof since that time. Since 1999, Mr. Leonsis has served as the Founder, Chairman, Majority Owner, and Chief Executive Officer of Monumental Sports & Entertainment, LLC, a sports, entertainment, media, and technology company that owns the NBA's Washington Wizards, the NHL's Washington Capitals, the WNBA's Washington Mystics, the Capital City Go Go, Wizards District Gaming, Caps Gaming, and Monumental Sports Network. Mr. Leonsis has served as a director of American Express Co. since July 2010. Mr. Leonsis has also served on the board of directors of Groupon, Inc. since June 2009, including as Chairman of the board of directors from August 2013 to November 2015 and, again, since June 2020. Mr. Leonsis also serves on the boards of directors of several private internet and technology companies, as well as charitable organizations. Mr. Leonsis holds a bachelor's degree from Georgetown University. - Theodore J. Leonsis，1999年以来他一直担任不朽体育及娱乐有限责任公司的董事长兼首席执行官，这是一家体育和娱乐公司在华盛顿特区和Verizon中心拥有NBA华盛顿奇才队，NHL华盛顿首都，WNBA华盛顿神秘主义者。他自2006年12月还担任美国在线公司名誉副主席，一家全球领先的广告网络公司。从1994年9月到2006年12月，他担任美国在线众多高管职位，比如说副主席和美国在线观众业务。他是Groupon公司的董事会主席。他也是一个导演，一个作家，几个私人网络和技术公司和教育机构的主人。他还是Revolution Money，Inc.的董事长，该公司是美国运通2010年1月取得的。2011年11月，他合伙成立了革命增长有限公司，加速投资科技企业。
- Theodore J. Leonsis has served as a member of the Tempus Board since January 2019 and is a member of the Nominating and Corporate Governance Committee and the Executive Committee. In November 2011, Mr. Leonsis co founded Revolution Growth, a private investment firm, and has served as a General Partner thereof since that time. Since 1999, Mr. Leonsis has served as the Founder, Chairman, Majority Owner, and Chief Executive Officer of Monumental Sports & Entertainment, LLC, a sports, entertainment, media, and technology company that owns the NBA's Washington Wizards, the NHL's Washington Capitals, the WNBA's Washington Mystics, the Capital City Go Go, Wizards District Gaming, Caps Gaming, and Monumental Sports Network. Mr. Leonsis has served as a director of American Express Co. since July 2010. Mr. Leonsis has also served on the board of directors of Groupon, Inc. since June 2009, including as Chairman of the board of directors from August 2013 to November 2015 and, again, since June 2020. Mr. Leonsis also serves on the boards of directors of several private internet and technology companies, as well as charitable organizations. Mr. Leonsis holds a bachelor's degree from Georgetown University.
- David R. Epstein
-
David R. Epstein，Novartis Pharmaceuticals（Novartis AG的一个部门）的部门主管兼首席执行官，兼任Novartis执行委员会的成员，Novartis AG是瑞士的跨国制药公司；自2010年起担任Novartis Pharmaceuticals的主管；2000年9月至2010年2月间担任Novartis肿瘤部门的总裁兼首席执行官；1989年加入Sandoz（Novartis的前身），担任Novartis Pharmaceuticals Corporation在美国的首席运营官和Novartis Specialty Medicines全球主管等多个职位，直至2000年8月；此前是Booz Allen Hamilton（咨询公司）的战略实践助理。他丰富的全球业务经验和对研发措施的理解，为董事会提供了重要见解。他于2008年至2010年间担任Molecular Insight Pharmaceuticals的董事，1999年至2010年间担任Novartis Oncology and Molecular Diagnostics的董事，参与the inaugural CEO Roundtable on Cancer（非营利性组织，旨在为消除癌症作出持续努力，2001年5月8日成立），2008年前都是the Novartis的成员代表。
David R. Epstein has served as a member of the Tempus Board since February 2024 and is a member of the Compensation Committee and the Nominating and Corporate Governance Committee. Mr. Epstein has served as the Chairman and Chief Executive Officer of Ottimo Pharma Limited since October 2024. Mr. Epstein also serves as a board member at privately held biotherapeutics companies Valo Health, LLC, and Agomab Therapeutics NV. He is a Director at the non profit Three Opinions Foundation Inc. and at South Florida's Pelican Harbor Seabird Station. Mr. Epstein previously served as the Chief Executive Officer and a member of the board of directors of Seagen Inc. from November 2022 until Seagen's acquisition by Pfizer Inc. in December 2023. From October 2021 to December 2023, Mr. Epstein served on the board of directors of OPY Acquisition Corp. I. From June 2022 to June 2023, Mr. Epstein served as a member of the board of directors of Senti Biosciences, Inc. and was previously a member of the board of Senti's predecessor, Dynamics Special Purpose Corp. since March 2021. From March 2017 to February 2023, he served as a director at Evelo Biosciences, Inc., including as the Chair of its board of directors from September 2019 to June 2022. From 2017 until October 2022, Mr. Epstein was a consultant and executive partner at Flagship Pioneering. From May 2019 to October 2022, Mr. Epstein served on the board of directors and as Chairman of Axcella Health Inc. (formerly Axcella Therapeutics) and, from January 2017 to October 2022, Mr. Epstein served on the board of directors of Rubius Therapeutics, Inc. From 2010 to mid 2016, he served as the Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, he started and led Novartis' Oncology and Molecular Diagnostic units. Under his leadership, Novartis' oncology business grew to the second largest in the world. Early in his career, he was an associate in the strategy practice of consulting firm Booz, Allen and Hamilton. Mr. Epstein holds a B.S. in pharmacy from Rutgers University College of Pharmacy and an M.B.A. in finance and marketing from Columbia University Graduate School of Business. - David R. Epstein，Novartis Pharmaceuticals（Novartis AG的一个部门）的部门主管兼首席执行官，兼任Novartis执行委员会的成员，Novartis AG是瑞士的跨国制药公司；自2010年起担任Novartis Pharmaceuticals的主管；2000年9月至2010年2月间担任Novartis肿瘤部门的总裁兼首席执行官；1989年加入Sandoz（Novartis的前身），担任Novartis Pharmaceuticals Corporation在美国的首席运营官和Novartis Specialty Medicines全球主管等多个职位，直至2000年8月；此前是Booz Allen Hamilton（咨询公司）的战略实践助理。他丰富的全球业务经验和对研发措施的理解，为董事会提供了重要见解。他于2008年至2010年间担任Molecular Insight Pharmaceuticals的董事，1999年至2010年间担任Novartis Oncology and Molecular Diagnostics的董事，参与the inaugural CEO Roundtable on Cancer（非营利性组织，旨在为消除癌症作出持续努力，2001年5月8日成立），2008年前都是the Novartis的成员代表。
- David R. Epstein has served as a member of the Tempus Board since February 2024 and is a member of the Compensation Committee and the Nominating and Corporate Governance Committee. Mr. Epstein has served as the Chairman and Chief Executive Officer of Ottimo Pharma Limited since October 2024. Mr. Epstein also serves as a board member at privately held biotherapeutics companies Valo Health, LLC, and Agomab Therapeutics NV. He is a Director at the non profit Three Opinions Foundation Inc. and at South Florida's Pelican Harbor Seabird Station. Mr. Epstein previously served as the Chief Executive Officer and a member of the board of directors of Seagen Inc. from November 2022 until Seagen's acquisition by Pfizer Inc. in December 2023. From October 2021 to December 2023, Mr. Epstein served on the board of directors of OPY Acquisition Corp. I. From June 2022 to June 2023, Mr. Epstein served as a member of the board of directors of Senti Biosciences, Inc. and was previously a member of the board of Senti's predecessor, Dynamics Special Purpose Corp. since March 2021. From March 2017 to February 2023, he served as a director at Evelo Biosciences, Inc., including as the Chair of its board of directors from September 2019 to June 2022. From 2017 until October 2022, Mr. Epstein was a consultant and executive partner at Flagship Pioneering. From May 2019 to October 2022, Mr. Epstein served on the board of directors and as Chairman of Axcella Health Inc. (formerly Axcella Therapeutics) and, from January 2017 to October 2022, Mr. Epstein served on the board of directors of Rubius Therapeutics, Inc. From 2010 to mid 2016, he served as the Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, he started and led Novartis' Oncology and Molecular Diagnostic units. Under his leadership, Novartis' oncology business grew to the second largest in the world. Early in his career, he was an associate in the strategy practice of consulting firm Booz, Allen and Hamilton. Mr. Epstein holds a B.S. in pharmacy from Rutgers University College of Pharmacy and an M.B.A. in finance and marketing from Columbia University Graduate School of Business.
高管简历
中英对照 | 中文 | 英文- Ryan Fukushima
Ryan Fukushima自2026年2月起担任Tempus的首席执行官，数据。福岛先生此前曾在2015年9月至2026年2月期间担任Tempus的首席运营官。在加入Tempus之前，福岛先生曾于2014年2月至2015年9月在Lightbank LLC（一家专门从事信息技术公司的私人投资公司）担任驻场企业家和副总裁。福岛先生于2021年7月至2025年5月期间担任Pathos AI，Inc.的首席执行官，目前担任Pathos AI，Inc.的顾问和董事会成员。福岛先生拥有加州理工大学的学士学位和密歇根大学罗斯商学院的工商管理硕士学位。
Ryan Fukushima has served as Tempus' Chief Executive Officer, Data since February 2026. Mr. Fukushima previously served as Tempus' Chief Operating Officer from September 2015 to February 2026. Prior to joining Tempus, Mr. Fukushima was an Entrepreneur in Residence and Vice President at Lightbank LLC, a private investment firm specializing in information technology companies, from February 2014 to September 2015. Mr. Fukushima served as the chief executive officer of Pathos AI, Inc. from July 2021 to May 2025 and currently serves as an advisor and a member of the board of directors of Pathos AI, Inc. Mr. Fukushima holds a B.S. from California Polytechnic University and an M.B.A. from the Ross School of Business at the University of Michigan.- Ryan Fukushima自2026年2月起担任Tempus的首席执行官，数据。福岛先生此前曾在2015年9月至2026年2月期间担任Tempus的首席运营官。在加入Tempus之前，福岛先生曾于2014年2月至2015年9月在Lightbank LLC（一家专门从事信息技术公司的私人投资公司）担任驻场企业家和副总裁。福岛先生于2021年7月至2025年5月期间担任Pathos AI，Inc.的首席执行官，目前担任Pathos AI，Inc.的顾问和董事会成员。福岛先生拥有加州理工大学的学士学位和密歇根大学罗斯商学院的工商管理硕士学位。
- Ryan Fukushima has served as Tempus' Chief Executive Officer, Data since February 2026. Mr. Fukushima previously served as Tempus' Chief Operating Officer from September 2015 to February 2026. Prior to joining Tempus, Mr. Fukushima was an Entrepreneur in Residence and Vice President at Lightbank LLC, a private investment firm specializing in information technology companies, from February 2014 to September 2015. Mr. Fukushima served as the chief executive officer of Pathos AI, Inc. from July 2021 to May 2025 and currently serves as an advisor and a member of the board of directors of Pathos AI, Inc. Mr. Fukushima holds a B.S. from California Polytechnic University and an M.B.A. from the Ross School of Business at the University of Michigan.
- Andrew Polovin
Andrew Polovin自2026年2月起担任Tempus的首席法务官。Polovin先生此前曾于2020年6月至2026年2月担任Tempus的总法律顾问，并自2024年4月起担任Tempus的执行副总裁兼秘书。2016年8月至2020年6月，Polovin先生担任Uptake Technologies，Inc.的总法律顾问和秘书，该公司是一家专门从事工业机械人工智能软件的公司。在转型帮助领导处于成长期的科技公司之前，Polovin先生是Bartlit Beck律师事务所的合伙人，该律师事务所是美国领先的审判精品店之一，曾担任伊利诺伊州北区的助理美国检察官，并担任美国上诉法院首席法官的书记员。Polovin先生拥有高露洁大学的学士学位和西北大学法学院的法学博士学位。
Andrew Polovin has served as Tempus' Chief Legal Officer since February 2026. Mr. Polovin previously served as Tempus' General Counsel from June 2020 to February 2026 and has served as Tempus' Executive Vice President and Secretary since April 2024. From August 2016 to June 2020, Mr. Polovin was the General Counsel and Secretary of Uptake Technologies, Inc., a company specializing in Artificial Intelligence software for industrial machinery. Before transitioning to help lead growth stage technology companies, Mr. Polovin was a partner at the law firm of Bartlit Beck, one of the nation's leading trial boutiques, served as an Assistant United States Attorney in the Northern District of Illinois, and clerked for the Chief Judge of the United States Court of Appeals. Mr. Polovin holds a B.A. from Colgate University and a J.D. from Northwestern University School of Law.- Andrew Polovin自2026年2月起担任Tempus的首席法务官。Polovin先生此前曾于2020年6月至2026年2月担任Tempus的总法律顾问，并自2024年4月起担任Tempus的执行副总裁兼秘书。2016年8月至2020年6月，Polovin先生担任Uptake Technologies，Inc.的总法律顾问和秘书，该公司是一家专门从事工业机械人工智能软件的公司。在转型帮助领导处于成长期的科技公司之前，Polovin先生是Bartlit Beck律师事务所的合伙人，该律师事务所是美国领先的审判精品店之一，曾担任伊利诺伊州北区的助理美国检察官，并担任美国上诉法院首席法官的书记员。Polovin先生拥有高露洁大学的学士学位和西北大学法学院的法学博士学位。
- Andrew Polovin has served as Tempus' Chief Legal Officer since February 2026. Mr. Polovin previously served as Tempus' General Counsel from June 2020 to February 2026 and has served as Tempus' Executive Vice President and Secretary since April 2024. From August 2016 to June 2020, Mr. Polovin was the General Counsel and Secretary of Uptake Technologies, Inc., a company specializing in Artificial Intelligence software for industrial machinery. Before transitioning to help lead growth stage technology companies, Mr. Polovin was a partner at the law firm of Bartlit Beck, one of the nation's leading trial boutiques, served as an Assistant United States Attorney in the Northern District of Illinois, and clerked for the Chief Judge of the United States Court of Appeals. Mr. Polovin holds a B.A. from Colgate University and a J.D. from Northwestern University School of Law.
- James Rogers
James 罗杰斯于2020年4月至2021年4月担任腾邦财务副总裁，并于2017年8月至2020年4月担任腾邦财务高级总监。在加入腾邦之前，罗杰斯先生于2011年4月至2017年8月在Groupon公司担任多个财务职务，包括最近于2017年2月至2017年8月领导北美业务的FP & A，并于2015年1月至2017年1月担任亚太业务的财务总监。罗杰斯先生拥有圣母大学的学士学位和北伊利诺伊大学的硕士学位。
James Rogers served as Tempus' Vice President of Finance from April 2020 to April 2021 and as Tempus' Senior Director of Finance from August 2017 to April 2020. Prior to joining Tempus, Mr. Rogers held various finance positions at Groupon, Inc. from April 2011 to August 2017, including most recently leading FP&A for the North America business from February 2017 to August 2017 and serving as the financial controller of Asia Pacific operations from January 2015 to January 2017. Mr. Rogers holds a B.B.A. from the University of Notre Dame and an M.S. from Northern Illinois University.- James 罗杰斯于2020年4月至2021年4月担任腾邦财务副总裁，并于2017年8月至2020年4月担任腾邦财务高级总监。在加入腾邦之前，罗杰斯先生于2011年4月至2017年8月在Groupon公司担任多个财务职务，包括最近于2017年2月至2017年8月领导北美业务的FP & A，并于2015年1月至2017年1月担任亚太业务的财务总监。罗杰斯先生拥有圣母大学的学士学位和北伊利诺伊大学的硕士学位。
- James Rogers served as Tempus' Vice President of Finance from April 2020 to April 2021 and as Tempus' Senior Director of Finance from August 2017 to April 2020. Prior to joining Tempus, Mr. Rogers held various finance positions at Groupon, Inc. from April 2011 to August 2017, including most recently leading FP&A for the North America business from February 2017 to August 2017 and serving as the financial controller of Asia Pacific operations from January 2015 to January 2017. Mr. Rogers holds a B.B.A. from the University of Notre Dame and an M.S. from Northern Illinois University.
- Tom Schoenherr
Tom Schoenherr自2026年2月起担任Tempus的首席执行官，Diagnostics。Schoenherr先生还自2021年5月起担任Ambry Genetics Corporation的首席执行官，并在Tempus于2025年2月收购Ambry后继续担任该职务。他此前曾在2017年11月至2021年5月期间担任Ambry的首席商务官。Schoenherr先生在分子诊断领域拥有超过20年的执行领导经验，包括在2016年8月至2017年8月期间担任Omada Health的首席商务官，该公司是一家用于慢性病管理的虚拟护理解决方案，并继续担任顾问。Schoenherr先生拥有密歇根州立大学的理学学士学位，并在圣母大学完成了高管业务发展计划。
Tom Schoenherr has served as Tempus' Chief Executive Officer, Diagnostics since February 2026. Mr. Schoenherr has also served as Chief Executive Officer of Ambry Genetics Corporation since May 2021 and has continued in that role following Tempus' acquisition of Ambry in February 2025. He previously served as Ambry's Chief Commercial Officer from November 2017 to May 2021. Mr. Schoenherr has over 20 years of executive leadership experience in the molecular diagnostics space, including serving as Chief Commercial Officer at Omada Health, a virtual care solution for chronic disease management, from August 2016 to August 2017, where he continues to serve as an advisor. Mr. Schoenherr holds a Bachelor of Science degree from Michigan State University and completed the Executive Business Development Program at the University of Notre Dame.- Tom Schoenherr自2026年2月起担任Tempus的首席执行官，Diagnostics。Schoenherr先生还自2021年5月起担任Ambry Genetics Corporation的首席执行官，并在Tempus于2025年2月收购Ambry后继续担任该职务。他此前曾在2017年11月至2021年5月期间担任Ambry的首席商务官。Schoenherr先生在分子诊断领域拥有超过20年的执行领导经验，包括在2016年8月至2017年8月期间担任Omada Health的首席商务官，该公司是一家用于慢性病管理的虚拟护理解决方案，并继续担任顾问。Schoenherr先生拥有密歇根州立大学的理学学士学位，并在圣母大学完成了高管业务发展计划。
- Tom Schoenherr has served as Tempus' Chief Executive Officer, Diagnostics since February 2026. Mr. Schoenherr has also served as Chief Executive Officer of Ambry Genetics Corporation since May 2021 and has continued in that role following Tempus' acquisition of Ambry in February 2025. He previously served as Ambry's Chief Commercial Officer from November 2017 to May 2021. Mr. Schoenherr has over 20 years of executive leadership experience in the molecular diagnostics space, including serving as Chief Commercial Officer at Omada Health, a virtual care solution for chronic disease management, from August 2016 to August 2017, where he continues to serve as an advisor. Mr. Schoenherr holds a Bachelor of Science degree from Michigan State University and completed the Executive Business Development Program at the University of Notre Dame.
- Eric Lefkofsky
Eric Lefkofsky，是该公司的联合创始人，自2013年8月5日创立以来担任公司执行董事长； 2013年2月28日以来在公司行政长官办事处任职，一直到2013年8月5日赴任首席执行官。Lefkofsky先生是Echo环球物流公司（NASDAQ代码： ECHO）的联合创始人， 2005年2月-2012年12月期间在该公司董事会任职。他也是InnerWorkings公司 （NASDAQ代码： INWK）的联合创始人，在2008年8月-2012年10月在该公司董事会任职。2008年，Lefkofsky联合创立了一家专门从事信息技术公司的私人投资公司- Lightbank有限责任公司，并从那时起担任经理。在2006年4月，Lefkofsky联合创立了一家促进广告媒体采购与管理自动化的电子交易与数据库的公司-MediaBank有限责任公司（现为Media Ocean），并从那时起担任董事或经理。Lefkofsky还分别在Children's Memorial 医院、Steppenwolf剧院、芝加哥美术馆（Art Institute of Chicago）、科学和工业博物馆（the Museum of Science and Industry）的董事会任职。Lefkofsky是芝加哥大学Booth商学院（the University of Chicago Booth School of Business）副教授；他拥有密歇根大学（he University of Chicago）的学士学位以及密歇根大学法学院（the University of Michigan Law School）的法学博士学位。
Eric Lefkofsky is Tempus' Founder, has served as its Chief Executive Officer and a member of the Tempus Board since its inception and is a member of the Executive Committee. Before founding Tempus, Mr. Lefkofsky co founded Groupon, Inc. in 2008, where he held various roles, including member of the board of directors (through November 2023), Chairman of the board of directors (November 2015 to June 2020), Executive Chairman (through August 2013) and Chief Executive Officer (August 2013 to November 2015). Mr. Lefkofsky also co founded Lightbank LLC in 2008, a private venture capital firm specializing in investments in technology companies, and has served as its managing member since inception and General Partner since January 2019. Mr. Lefkofsky also co founded InnerWorkings, Inc., Mediaocean, LLC, Echo Global Logistics, Inc., and Pathos AI, Inc., and served on each company's board of directors or board of managers. In addition, Mr. Lefkofsky has served on the board of directors of Northwestern Memorial Healthcare since February 2024. Mr. Lefkofsky holds a bachelor's degree from the University of Michigan and a J.D. from the University of Michigan Law School.- Eric Lefkofsky，是该公司的联合创始人，自2013年8月5日创立以来担任公司执行董事长； 2013年2月28日以来在公司行政长官办事处任职，一直到2013年8月5日赴任首席执行官。Lefkofsky先生是Echo环球物流公司（NASDAQ代码： ECHO）的联合创始人， 2005年2月-2012年12月期间在该公司董事会任职。他也是InnerWorkings公司 （NASDAQ代码： INWK）的联合创始人，在2008年8月-2012年10月在该公司董事会任职。2008年，Lefkofsky联合创立了一家专门从事信息技术公司的私人投资公司- Lightbank有限责任公司，并从那时起担任经理。在2006年4月，Lefkofsky联合创立了一家促进广告媒体采购与管理自动化的电子交易与数据库的公司-MediaBank有限责任公司（现为Media Ocean），并从那时起担任董事或经理。Lefkofsky还分别在Children's Memorial 医院、Steppenwolf剧院、芝加哥美术馆（Art Institute of Chicago）、科学和工业博物馆（the Museum of Science and Industry）的董事会任职。Lefkofsky是芝加哥大学Booth商学院（the University of Chicago Booth School of Business）副教授；他拥有密歇根大学（he University of Chicago）的学士学位以及密歇根大学法学院（the University of Michigan Law School）的法学博士学位。
- Eric Lefkofsky is Tempus' Founder, has served as its Chief Executive Officer and a member of the Tempus Board since its inception and is a member of the Executive Committee. Before founding Tempus, Mr. Lefkofsky co founded Groupon, Inc. in 2008, where he held various roles, including member of the board of directors (through November 2023), Chairman of the board of directors (November 2015 to June 2020), Executive Chairman (through August 2013) and Chief Executive Officer (August 2013 to November 2015). Mr. Lefkofsky also co founded Lightbank LLC in 2008, a private venture capital firm specializing in investments in technology companies, and has served as its managing member since inception and General Partner since January 2019. Mr. Lefkofsky also co founded InnerWorkings, Inc., Mediaocean, LLC, Echo Global Logistics, Inc., and Pathos AI, Inc., and served on each company's board of directors or board of managers. In addition, Mr. Lefkofsky has served on the board of directors of Northwestern Memorial Healthcare since February 2024. Mr. Lefkofsky holds a bachelor's degree from the University of Michigan and a J.D. from the University of Michigan Law School.